Skip to Main Content

Paper Details

Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Am J Cancer Res
32
2020
-, BRCA1/2, EGFR, PARP, PARPi, PARPi-resistant cells, RTKs, TNBC, TNBC cells, c, c-MET, c-MET-depleted TNBC cells, c-Met, crizotinib, epidermal growth factor receptor, hepatocyte growth factor receptor, metastatic breast cancer, neoplastic, olaparib, patients, poly (ADP-ribose), poly (ADP-ribose) polymerase, receptor tyrosine kinases, resistant cells, talazoparib, triple-negative breast cancer, tyrosine
Author NameAffiliation
Kenneth R HessThe University of Texas MD Anderson Cancer Center Houston
Kenneth R HessThe University of Texas MD Anderson Cancer Center Houston
Gabriel N HortobagyiThe University of Texas MD Anderson Cancer Center Houston
Mien-Chie HungGraduate Institute of Biomedical Sciences, Research Center for Cancer Biology, Center for Molecular Medicine, China Medical University Taichung
Mien-Chie HungThe University of Texas MD Anderson Cancer Center Houston
Mien-Chie HungAsia University Taichung
  • 1 - 6

Datasets

Release 1.2